Kalaris Therapeutics, Inc.
corporate_fare Company Profile
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KLRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for KLRS spans 10-Q, 8-K, 424B3, S-3.
Recent high-impact activity:
- Kalaris 10-Q: Material Weaknesses Persist, TH103 Phase 1b/2 Data Slipped to 2H 2027
- Kalaris Extends Cash Runway Into 2028, But TH103 Data Slips to 2H 2027
- Kalaris Posts $11.5M Q2 Loss, Cash Runway Into Q4 2027; Phase 1b/2 Data Due 1H 2027
- Kalaris Unveils Expanded Phase 1a Data for TH103 in nAMD, Highlighting Durable Responses and a Clean Safety Profile at the 2.5 mg Dose
- TH103 Shows Durable Responses in Expanded AMD Trial, 29% Treatment-Free at 6 Months
Financial Snapshot
Short Interest & Short Volume
5.43 days to coverFINRA reported short interest of 366,632 shares in KLRS as of the October 30, 2026 settlement, a 19.7% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On November 19, 2026, 27.4% of KLRS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.